Company Analysis
Sign in

ADC Therapeutics SA (ADCT)

NYSE: ADCT · Pharmaceutical Preparations · Epalinges, CH · filing with the SEC since 2019
Full chart Alerts Compare
Grade5.3
◀ Past 5.5● Present 4.8▶ Future 6.0
2 est.
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart

Patents

US patents through Dec 31, 2025 · PatentsView, from the USPTO’s Open Data Portal · read Oct 27, 2026

22 patents granted to the 2 names below, as the owner printed on each patent when it was granted. A later sale, a lapse or an expiry is not read, so this is what was granted to ADC Therapeutics SA’s names, not what it holds today.

Patents granted
22
22 utility, 1976 to Dec 31, 2025
Granted in 2025
none
Against 2 in 2024 and 4 in 2023
Applications published
68
7 of them in 2025
Names they are printed under
2
its own name
By yearGrantedApplications published
'15'16'17'18'19'20'21'22'23'24'25
Each pair is one calendar year. Applications are published about eighteen months after filing, so the newest years read low.
What they are aboutgrants since 2021
Pharmaceuticals10
Biotechnology1
The main technology area of each patent, in the World Intellectual Property Organization’s 35 fields.
Under which name2 counted
ADC THERAPEUTICS SA its own name
named as the applicant on its applications, in CH. 1 more under the same name are not counted (printed in SZ)
0 granted
67 published
ADC THERAPEUTICS SA its own name
CH, as the owner printed on each patent
22 granted
1 published
Newest grantseach row opens the USPTO’s own copy
GrantedPatentTitleFieldOwner as printed
May 7, 202411,976,122Anti-IL13Rα2 antibodiesBiotechnologyADC THERAPEUTICS SA
Mar 26, 202411,938,192Dosage regimes for the administration of an anti-CD19 ADCPharmaceuticalsADC THERAPEUTICS SA
Nov 14, 202311,813,335Pyrrolobenzodiazepine-antibody conjugatesPharmaceuticalsADC THERAPEUTICS SA
Jul 18, 202311,702,473Site-specific antibody-drug conjugatesPharmaceuticalsADC THERAPEUTICS SA
Jul 4, 202311,690,918Pyrrolobenzodiazepine-anti-CD22 antibody conjugatesPharmaceuticalsADC THERAPEUTICS SA
Mar 7, 202311,596,696Combination therapy with an anti-CD25 antibody-drug conjugatePharmaceuticalsADC THERAPEUTICS SA
Aug 30, 202211,426,467Dosage regimes for the administration of an anti-CD25 ADCPharmaceuticalsADC THERAPEUTICS SA
Jul 12, 202211,384,098Pyrrolobenzodiazepine-antibody conjugatesPharmaceuticalsADC THERAPEUTICS SA
May 3, 202211,318,211Dosage regimes for the administration of an anti-CD19 ADCPharmaceuticalsADC THERAPEUTICS SA
Nov 2, 202111,160,872Pyrrolobenzodiazepine-antibody conjugatesPharmaceuticalsADC THERAPEUTICS SA
Newest applications publishedan application is a clue, never a plan
PublishedApplicationTitleFieldOwner as printed
Dec 18, 20252025/0381282COMPOSITION COMPRISING A PYRROLOBENZODIAZEPINE-BASED ANTIBODY DRUG CONJUGATEPharmaceuticalsADC THERAPEUTICS SA
Nov 20, 20252025/0352658COMBINATION THERAPY USING ANTIBODY-DRUG CONJUGATESPharmaceuticalsADC THERAPEUTICS SA
Jun 12, 20252025/0186604ANTI-PSMA ANTIBODY CONJUGATESPharmaceuticalsADC THERAPEUTICS SA
May 29, 20252025/0170258DOSAGE REGIMENPharmaceuticalsADC THERAPEUTICS SA
May 22, 20252025/0163488CONJUGATION METHOD INVOLVING A TRANSGLUTAMINASE AT THE FC REGION COMPRISING A TRIMMED N-GLYCANBiotechnologyADC THERAPEUTICS SA
May 15, 20252025/0152725COMBINATION THERAPY WITH AN ANTI-AXL ANTIBODY-PBD CONJUGATE AND NANOCUPSPharmaceuticalsADC THERAPEUTICS SA
Apr 17, 20252025/0121084ANTI-CLAUDIN-6 CONJUGATESPharmaceuticalsADC THERAPEUTICS SA
Aug 15, 20242024/0269314PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES AND USES THEREOFPharmaceuticalsADC THERAPEUTICS SA
Sep 14, 20232023/0285580ANTI-IL-13RALPHA2 CONJUGATESPharmaceuticalsADC THERAPEUTICS SA
Jun 29, 20232023/0201366ANTI-PSMA CONJUGATESPharmaceuticalsADC THERAPEUTICS SA
What it applied for, 2024 to 2025: Pharmaceuticals 7 · Biotechnology 1.

A patent is counted where the owner printed on it when it was granted carries the company’s own name, a former name, the name of a subsidiary its annual report lists, or its own name with a patent-holding phrase (Technology Licensing, Intellectual Property and the like), once the legal form, case and punctuation are set aside, and prints a country that name counts in. PatentsView’s data are published under the Creative Commons Attribution 4.0 licence. Source: PatentsView's granted patents and pre-grant publications, disambiguated, from the USPTO's Open Data Portal, through Dec 31, 2025, read Oct 27, 2026.

SI Assistanton ADCT · research, not advice